We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The NHS’ cost effectiveness body NICE has rejected two treatments for the rare inherited condition, hereditary transthyretin-related amyliodsis (hATTR), over concerns as to whether the drugs showed long term benefits.
The FDA has delayed the PDUFA date for Akcea’s hereditary TTR amyloidosis drug inotersen, handing first-mover advantage to Alnylam. Akcea suffered the setback after the FDA asked for more time to review its response to requests for information ...